IONIS PHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
IONS$39.42+1.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
| ITEM 5. | OTHER INFORMATION |
|---|
Trading Plans
During the quarter ended March 31, 2024, our Section 16 officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted in the table below.
| * | Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. |
|---|
| ** | “Non-Rule 10b5-1 trading arrangement” as defined in item 408(c) of Regulation S-K under the Exchange Act. |
|---|
| Action | Date | Trading Arrangement | Total Shares to Be Sold | Expiration Date | |
|---|---|---|---|---|---|
| Rule 10b5-1* | Non-Rule 10b5-1** | ||||
| B. Lynne Parshall Board Member | Termination | January 3, 2024 | X | 122,638 | Upon the execution of all instructions provided in the plan |
| Joseph Klein, III Board Member | Adoption | January 3, 2024 | X | 82,000 | The earlier to occur of (i) December 31, 2025, and (ii) Upon the execution of all instructions provided in the plan |
| Joseph Baroldi EVP, Chief Business Officer | Adoption | January 5, 2024 | X | 40,000 | The earlier to occur of (i) March 31, 2025, and (ii) Upon the execution of all instructions provided in the plan |
| Eugene Schneider EVP, Chief Clinical Development and Operations Officer | Adoption | January 12, 2024 | X | 40,633 | The earlier to occur of (i) July 29, 2025, and (ii) Upon the execution of all instructions provided in the plan |
| Elizabeth Hougen EVP, Finance & Chief Financial Officer | Adoption | January 12, 2024 | X | 178,200 | The earlier to occur of (i) October 11, 2025, and (ii) Upon the execution of all instructions provided in the plan |
| Patrick O'Neil Chief Legal Officer & General Counsel | Termination | February 14, 2024 | X | 170,830 | Upon the execution of all instructions provided in the plan |
| B. Lynne Parshall Board Member | Adoption | February 21, 2024 | X | 145,568 | The earlier to occur of (i) June 30, 2025, and (ii) Upon the execution of all instructions provided in the plan |
| Patrick O'Neil Chief Legal Officer & General Counsel | Adoption | February 21, 2024 | X | 252,747 | The earlier to occur of (i) May 31, 2025, and (ii) Upon the execution of all instructions provided in the plan |
Index
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.